Defence Therapeutics Inc.
DTCFF
$0.66
$0.047.21%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -72.73% | -76.04% | -61.31% | -67.19% | 136.88% |
| Depreciation & Amortization | -27.88% | -22.31% | 130.41% | 405.84% | 256.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.61% | -76.75% | -64.36% | -63.15% | 70.68% |
| Operating Income | 72.61% | 76.75% | 64.36% | 63.15% | -70.68% |
| Income Before Tax | 69.68% | 74.08% | 73.59% | 70.43% | -56.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.68% | 74.08% | 73.38% | 70.20% | -58.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.68% | 74.08% | 73.38% | 70.20% | -58.48% |
| EBIT | 72.61% | 76.75% | 64.36% | 63.15% | -70.68% |
| EBITDA | 72.83% | 77.03% | 64.86% | 63.67% | -70.29% |
| EPS Basic | 73.74% | 76.80% | 74.81% | 71.48% | -46.24% |
| Normalized Basic EPS | 73.11% | 76.26% | 74.08% | 71.72% | -44.18% |
| EPS Diluted | 73.74% | 76.80% | 74.81% | 71.48% | -46.24% |
| Normalized Diluted EPS | 73.11% | 76.26% | 74.08% | 71.72% | -44.18% |
| Average Basic Shares Outstanding | 13.96% | 9.86% | 6.05% | 6.96% | 9.85% |
| Average Diluted Shares Outstanding | 13.96% | 9.86% | 6.05% | 6.96% | 9.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |